AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announced today its initial research engagement with TransBIOTech.
VANCOUVER, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- AREV Life Sciences Global Corp. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) announced today its initial research engagement with TransBIOTech.
Created in 1999, TransBIOTech is a publicly supported preclinical research organization that works in partnership with and is supported by the Canadian government through the Natural Sciences and Engineering Research Council (NSERC) in collaboration with the Canadian Institutes of Health Research (CIHR). TransBIOTech is also supported by the Canadian Foundation for Innovation and by the Government of Quebec. TransBIOTech is a member of Tech-Access Canada, a national organization of Technology Access Centres (TACs), as well as a member of Synchronex, a network of Quebec province College Centres for the Transfer of Technologies (CCTT). TransBIOTech laboratory facility utilizes more than $16 million in state-of-the-art equipment and offers an animal facility accredited by the Council on Animal Care of Canada (source: https://www.tbt.qc.ca/en/facilities/).
TransBIOTech is a multi-sectional research facility with expertise in the life sciences sector, specializing in analytical chemistry, biochemistry, cell & molecular biology, and microbiology for pharmaceutical sciences. TransBIOTech has capabilities in various project stages including in vitro, in cellulo and in vivo functional assays (biomarkers, cytotoxicity, anti-inflammatory properties and antimicrobial activity, as well as analysis of pharmacological properties of molecules including permeability, metabolic stability, ADME and toxicology).
“TransBIOTech is engaging with AREV in its initial research on cannabinoids and other early-stage commercial research programs. Our agreement with TransBIOTech signals the initiation of a robust clinical initiative with numerous collaborators to facilitate data on some of the more promising phytomedicinal therapeutics currently relevant to today’s public health challenges,” said AREV CEO Mike Withrow.
Withrow also stated, “AREV Life Sciences is determined to enhance our scientific acumen by partnering with dynamic programs that will facilitate breakthrough discoveries of therapeutic innovation relevant to contemporary pandemic infectious disease and human nutrition. By leveraging our proprietary extraction technologies paired with the discovery capacities of TransBIOTech and other well-respected research institutions, we are laying the groundwork for initial animal studies to identify data sets that will satisfy regulatory authorities.”
Recent preclinical studies have purported that CBD modulates anti-inflammatory effects. Clinical studies have verified that CBD lowers the levels of pro-inflammatory cytokines, suppresses T-cell proliferation, creates T-cell apoptosis and lowers migration and adhesion of immune cells. It has also been discovered that this CBD-driven anti-inflammatory action displays itself to be antagonized by both a CB2 antagonist and a CB2 receptor agonist (source: https://www.frontiersin.org/articles/10.3389/fphar.2017.00144/full). The TransBIOTech collaboration with AREV will also examine precise mechanisms of action attributed to the activation of CB2 as a novel therapeutic modality modulating inflammation characteristic of viral infections (source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005548/).
The collaboration between AREV and TransBIOTech will facilitate further development of proprietary immune modulatory therapeutics derived from phytomedicinal research that addresses pandemic infectious disease affecting host responses to elevated cytokine expression.
The initial studies will set the groundwork for advancing further research, allowing for distinctive understandings of AREV’s new chemical entity development including initial toxicity, pharmacokinetics and metabolism modeling essential for human studies and eventual commercialization. The reduction of pathogen mediated inflammation and subsequent immune hyperactivation by the inhibition of the mTOR/S6K-signaling progression, which is affected by cannabinoids CB1 receptor, also prohibits Jurkat cells from expressing regulation of immune responses (source: https://www.nature.com/articles/4401660). In vivo studies have demonstrated mTOR expression affected by cannabinoid regulatory mechanisms leading to autophagy in cancer cell pathways necessary for the antitumor actions (source: https://www.jci.org/articles/view/37948).
AREV, in conjunction with TransBIOTech, is also designing preclinical characterization studies to identify suspected therapeutic characteristics of other botanically derived compounds identified in peer-reviewed literature, including phytocannabinoids and Cucumaria frondosa, leading to small molecule candidates for human studies.
Edouard Lauzer, of TransBioTech, stated, “Our preclinical characterization research with TransBIOTech is an important step in AREV’s efforts to deliver well-defined clinical insights into the multidimensional aspects of immune modulation associated with CBD and other compounds derived from phytomedicinal drug development. AREV’s efforts with TransBIOTech will include characterizing the mechanism-of-action of CBD as well as analysis of the structure-activity relationships of secondary metabolites through fragment-based lead discovery and de novo drug design, utilizing high through-put screening to identify structural-functional relations of AREV’s investigational compounds affecting pathogen-mediated inflammation and viral replication.”
The initial studies being designed by TransBIOTech, in collaboration with members of the AREV Scientific Advisory Board (SAB), will provide correspondence of the subsequent published results of these studies to public research programs, including The National Institute of Health’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (NIH ACTIV), AIDS Clinical Trial Groups (NIAID ACTGs) of the National Institute of Allergy and Infectious Diseases and President Biden’s White House Cancer Cabinet.
For further information, contact Mike Withrow, arevlifesciences@gmail.com or 778-929-6536, or visit www.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO & Director
ABOUT AREV Life Sciences Global Corp.
AREV Life Sciences Global Corp. is a publicly traded, fully integrated, early-stage life science enterprise, with a U.S. subsidiary dedicated to delivering therapeutic interventions to public health through extraction of unique compounds, discovery, innovation and successful collaborations. The Company’s leadership drives discovery programs for clinical complexities presented by malnutrition, viral infectious diseases and elevated inflammatory responses. AREV is invested in commercial innovations in phytomedicinal discoveries of small molecule antivirals and for related neglected chronic co-morbidities and innovations in human nutrition. In addition to its phytomedicinal discovery program, AREV is developing a next-generation Ready-to-Use Therapeutic Food (RUTF). SUSTAINN is designed by AREV in collaboration with the Richardson Centre for Functional Foods and Nutraceuticals at the University of Manitoba that demonstrates clinical attributes addressing serious acute malnutrition (SAM). AREV is dedicated to designing and delivering innovation in rational drug design, driven by presenting global epidemiological characteristics of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and The Biotechnology Innovation Organization (BIO).
This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements.” Forward-looking statements can be identified by the use of words such as “plans,” “expects” or “does not expect,” “is expected,” “estimates,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases or statements that certain actions, events or results “may,” “could,” “would,” “might” or “will” be taken, occur or be achieved. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements.
THE CSE HAS NEITHER APPROVED NOR DISAPPROVED THE INFORMATION CONTAINED HEREIN AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
